{"product_id":"proteogenix-sibeprenlimab-biosimilar-anti-tnfsf13-mab-research-grade","title":"Sibeprenlimab Biosimilar – Anti-TNFSF13 mAb – Research Grade","description":"\u003cp\u003eTitle: Understanding Sibeprenlimab Biosimilar: A Promising Anti-TNFSF13 mAb for Therapeutic Targeting\u003c\/p\u003e \u003ch3\u003eIntroduction\u003c\/h3\u003e \u003cp\u003eSibeprenlimab Biosimilar, also known as anti-TNFSF13 monoclonal antibody (mAb), is a novel biologic agent that has shown great potential in the treatment of various immune-mediated diseases. This biosimilar is a highly specific and potent inhibitor of TNFSF13, a cytokine involved in the regulation of immune responses and inflammation. In this article, we will delve into the structure, activity, and potential applications of Sibeprenlimab Biosimilar as a therapeutic agent.\u003c\/p\u003e \u003ch3\u003eStructure of Sibeprenlimab Biosimilar\u003c\/h3\u003e \u003cp\u003eSibeprenlimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region responsible for antigen binding and a constant region responsible for effector functions. The variable regions of Sibeprenlimab Biosimilar are engineered to specifically target and bind to TNFSF13, thereby blocking its activity.\u003c\/p\u003e \u003ch3\u003eActivity of Sibeprenlimab Biosimilar\u003c\/h3\u003e \u003cp\u003eTNFSF13, also known as B lymphocyte stimulator (BLyS), is a cytokine that plays a crucial role in the survival and maturation of B cells. It is also involved in the development of autoimmunity and inflammation. Sibeprenlimab Biosimilar binds to TNFSF13 and prevents its interaction with its receptor, thereby inhibiting the survival and activation of B cells. This leads to a decrease in the production of autoantibodies and pro-inflammatory cytokines, resulting in the suppression of autoimmune responses and inflammation.\u003c\/p\u003e \u003ch3\u003ePotential Applications of Sibeprenlimab Biosimilar\u003c\/h3\u003e \u003cp\u003eSibeprenlimab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various immune-mediated diseases. Some of the potential applications of this biosimilar include:\u003c\/p\u003e \u003cp\u003e1. Rheumatoid Arthritis (RA): RA is a chronic autoimmune disease characterized by joint inflammation and destruction. Sibeprenlimab Biosimilar has shown to be effective in reducing disease activity and improving clinical symptoms in RA patients.\u003c\/p\u003e \u003cp\u003e2. Systemic Lupus Erythematosus (SLE): SLE is a systemic autoimmune disease that affects multiple organs. Sibeprenlimab Biosimilar has shown to be effective in reducing disease activity and improving organ involvement in SLE patients.\u003c\/p\u003e \u003cp\u003e3. Sjögren’s Syndrome (SS): SS is an autoimmune disease that primarily affects the salivary and lacrimal glands, resulting in dry mouth and eyes. Sibeprenlimab Biosimilar has shown to improve salivary and lacrimal gland function in SS patients.\u003c\/p\u003e \u003cp\u003e4. Primary Sjögren’s Syndrome (pSS): pSS is a subtype of SS that occurs without any underlying connective tissue disease. Sibeprenlimab Biosimilar has shown to be effective in reducing disease activity and improving clinical symptoms in pSS patients.\u003c\/p\u003e \u003cp\u003e5. Other Autoimmune Diseases: Sibeprenlimab Biosimilar has also shown potential in the treatment of other autoimmune diseases such as systemic sclerosis, myasthenia gravis, and immune thrombocytopenia.\u003c\/p\u003e \u003ch3\u003eConclusion\u003c\/h3\u003e \u003cp\u003eSibeprenlimab Biosimilar is a promising biologic agent that specifically targets TNFSF13 and has shown great potential in the treatment of various immune-mediated diseases. Its unique mechanism of action and favorable safety profile make it a promising therapeutic option for patients with these conditions. Further studies are needed to fully understand the potential of this biosimilar and its role in the management of autoimmune diseases.\u003c\/p\u003e\u003cp\u003eProteoGenix catalogue number PX-TA1715. For research use only.\u003c\/p\u003e\u003cp\u003eTarget: Sibeprenlimab Biosimilar – Anti-TNFSF13 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: \u0026gt;85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.\u003c\/p\u003e\u003cp\u003eAvailable configurations: 50ug, 100ug, 1mg.\u003c\/p\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.proteogenix.science\/wp-content\/uploads\/documents\/Datasheets\/PX-TA1715.pdf\"\u003eDownload the manufacturer datasheet\u003c\/a\u003e\u003c\/p\u003e","brand":"ProteoGenix","offers":[{"title":"50ug","offer_id":57357690929492,"sku":"ABM134333-1","price":108.0,"currency_code":"GBP","in_stock":true},{"title":"100ug","offer_id":57357690962260,"sku":"ABM134333-2","price":180.0,"currency_code":"GBP","in_stock":true},{"title":"1mg","offer_id":57357690995028,"sku":"ABM134333-3","price":348.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1040\/1782\/2036\/files\/bioactivity-validation-1-sibeprenlimab-biosimilar-anti-tnfsf13-mab-research-grade_9eaaf7bd-1350-41ff-a50b-83db1dc649c9.jpg?v=1790890924","url":"https:\/\/www.abmium.com\/es\/products\/proteogenix-sibeprenlimab-biosimilar-anti-tnfsf13-mab-research-grade","provider":"ABMIUM","version":"1.0","type":"link"}